Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus
NCT ID: NCT05101915
Last Updated: 2024-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
6 participants
INTERVENTIONAL
2021-11-01
2024-04-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To assess the safety and tolerability of RESP301 during treatment (28 days) and follow up (84 days) in patients with cystic fibrosis who have treatment naïve or treatment refractory M. abscessus-pulmonary disease
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
NCT02694393
Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
NCT02498535
Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis
NCT00721071
Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation
NCT02480270
The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
NCT03870841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will treat particpants with cystic fibrosis (CF) attending the Adult Cystic Fibrosis Centre at the Royal Papworth Hospital, Cambridge, United Kingdom. Participants will be consented and screened for the RESP301-003 study to enable approximately 12 participants to commence treatment with RESP301.
Participants will have M abscessus-PD as defined by the ATS/IDSA, specifically: (i) two or more positive sputum cultures for M. abscessus; (ii) radiological change consistent with NTM-PD; and (iii) symptoms consistent with NTM-PD, after exclusion of other causes.
Participants will be recruited who (1) have not commenced antibiotic treatment for M. abscessus-PD or (2) have treatment refractory M. abscessus-PD (defined as remaining sputum culture positive after 6 months or more of treatment). Treatment-refractory participants will be suitable for enrolment in the study if date of first dosing is at least 2 months since a change in M. abscessus treatment (or 4 months since change of Clofazimine).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional
Single arm trial involving all patients receiving IMP
RESP301
Inhaled IMP delivered via nebulisation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RESP301
Inhaled IMP delivered via nebulisation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with a clinical diagnosis of CF and confirmed by genetic testing
3. Diagnosis of treatment naïve or treatment refractory M. abscessus-PD
4. Signed informed consent documentation (indicating an understanding of the purpose and a willingness to meet the requirements for participation in the study)
Exclusion Criteria
2. Methaemoglobin concentration \> 2%
3. Use of nitric oxide donor medications such as prilocaine, sodium nitroprusside, and nitroglycerine within 30 days of proposed first treatment
4. Use of phosphodiesterase inhibitors (e.g., sildenafil) within 30 days of proposed first treatment
5. Evidence of pulmonary hypertension
6. History of frequent low volume or massive haemoptysis
7. Liver disease (i.e. liver cirrhosis, portal hypertension)
8. Subjects who have undergone organ transplantation
9. Pregnancy or lactation (female participants only)
10. Subjects who will not use appropriate forms of contraception for the duration of the study
11. Contraindication or unable to complete lung function testing
12. Contraindication or unable to tolerate nebulised hypertonic saline
13. Changes to previous NTM antibiotic regimen within two months of first dose of study treatment (or 4 months for clofazimine)
14. Subject has received investigational treatment as part of another interventional clinical trial within two months of the proposed first day of treatment
15. Required antibiotic treatment for a pulmonary exacerbation within 2 weeks of enrolment to the study.
16. Inability to undergo study related activities and / or commitments
17. Any subject who in the opinion of the investigator would not be best served by participating in this clinical trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Papworth Hospital NHS Foundation Trust
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Papworth Hospital NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P02702
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.